High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer.
Standard
High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. / Jacobsen, Frank; Ashtiani, Sharad Nouraie; Tennstedt, Pierre; Heinzer, Hans; Simon, Ronald; Sauter, Guido; Sirma, Hüseyin; Tsourlakis, Maria Christina; Minner, Sarah Jane Pauline; Schlomm, Thorsten; Michl, Uwe.
in: EXP THER MED, Jahrgang 5, Nr. 1, 1, 2013, S. 102-106.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer.
AU - Jacobsen, Frank
AU - Ashtiani, Sharad Nouraie
AU - Tennstedt, Pierre
AU - Heinzer, Hans
AU - Simon, Ronald
AU - Sauter, Guido
AU - Sirma, Hüseyin
AU - Tsourlakis, Maria Christina
AU - Minner, Sarah Jane Pauline
AU - Schlomm, Thorsten
AU - Michl, Uwe
PY - 2013
Y1 - 2013
N2 - c-MET is considered a possible therapeutic target in numerous tumor types and is also a candidate regulator of response to anti-HER2 and anti-epidermal growth factor receptor (EGFR) therapy. The aim of this study was to determine the prevalence and clinical significance of c-MET expression in hormone-naïve prostate cancers. A pre-existing prostate tissue microarray (TMA) containing samples of 4,177 patients treated by radical prostatectomy was used. A total of 3,378 different prostate cancers were successfully analyzed for c-MET expression by immunohistochemistry and follow-up data were available for 4,104 patients. Membranous c-MET immunostaining was performed for 2,655 (78.6%) tumors. High c-MET protein expression was significantly associated with a high Gleason grade (P=0.0018). However, c-MET was not a prognostic marker for biochemical recurrence. c-MET levels were also not associated with other parameters, including tumor stage, nodal stage and surgical margin status. The c-MET protein is often overexpressed in prostate cancer, but has no prognostic relevance. However, the frequent presence of high levels of membranous c-MET protein in prostate cancer cells makes c-MET an attractive target for imaging and treatment.
AB - c-MET is considered a possible therapeutic target in numerous tumor types and is also a candidate regulator of response to anti-HER2 and anti-epidermal growth factor receptor (EGFR) therapy. The aim of this study was to determine the prevalence and clinical significance of c-MET expression in hormone-naïve prostate cancers. A pre-existing prostate tissue microarray (TMA) containing samples of 4,177 patients treated by radical prostatectomy was used. A total of 3,378 different prostate cancers were successfully analyzed for c-MET expression by immunohistochemistry and follow-up data were available for 4,104 patients. Membranous c-MET immunostaining was performed for 2,655 (78.6%) tumors. High c-MET protein expression was significantly associated with a high Gleason grade (P=0.0018). However, c-MET was not a prognostic marker for biochemical recurrence. c-MET levels were also not associated with other parameters, including tumor stage, nodal stage and surgical margin status. The c-MET protein is often overexpressed in prostate cancer, but has no prognostic relevance. However, the frequent presence of high levels of membranous c-MET protein in prostate cancer cells makes c-MET an attractive target for imaging and treatment.
M3 - SCORING: Journal article
VL - 5
SP - 102
EP - 106
JO - EXP THER MED
JF - EXP THER MED
SN - 1792-0981
IS - 1
M1 - 1
ER -
